TY - JOUR
T1 - Combination Biologic Therapy in Inflammatory Bowel Disease
T2 - Experience From a Tertiary Care Center
AU - Kwapisz, Lukasz
AU - Raffals, Laura E.
AU - Bruining, David H.
AU - Pardi, Darrell S.
AU - Tremaine, William J.
AU - Kane, Sunanda V.
AU - Papadakis, Konstantinos A.
AU - Coelho-Prabhu, Nayantara
AU - Kisiel, John B.
AU - Heron, Valerie
AU - Faubion, William A.
AU - Loftus, Edward V.
N1 - Funding Information:
Conflicts of interest These authors disclose the following: Laura Raffals: consulting Pfizer, honorarium paid to Mayo Clinic. Darrell Pardi: consulting Janssen, Merck, Pfizer, Gilead; grant/research support: Janssen, Merck, Pfizer, Takeda . Konstantinos Papadakis: stock shareholder: Pfizer, GlaxoSmithKline plc, Johnson & Johnson. Sunanda Kane: consulting AbbVie. William Faubion: consulting AbbVie, Janssen, Robarts, Shire, MediBeacon Inc, Boehringer Ingelheim Pharma, S&B Pharma Inc/Norac Pharma. Edward Loftus: consulting AbbVie, Allergan, Amgen, Boehringer Ingelheim , Bristol-Myers Squibb, Celgene, Celltrion Healthcare, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Takeda , UCB; research support: from AbbVie, Amgen, Celgene, Genentech, Gilead, Janssen, Medimmune, Pfizer, Robarts Clinical Trials, Takeda , UCB . The remaining authors disclose no conflicts.
Funding Information:
Conflicts of interest These authors disclose the following: Laura Raffals: consulting Pfizer, honorarium paid to Mayo Clinic. Darrell Pardi: consulting Janssen, Merck, Pfizer, Gilead; grant/research support: Janssen, Merck, Pfizer, Takeda. Konstantinos Papadakis: stock shareholder: Pfizer, GlaxoSmithKline plc, Johnson & Johnson. Sunanda Kane: consulting AbbVie. William Faubion: consulting AbbVie, Janssen, Robarts, Shire, MediBeacon Inc, Boehringer Ingelheim Pharma, S&B Pharma Inc/Norac Pharma. Edward Loftus: consulting AbbVie, Allergan, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion Healthcare, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Takeda, UCB; research support: from AbbVie, Amgen, Celgene, Genentech, Gilead, Janssen, Medimmune, Pfizer, Robarts Clinical Trials, Takeda, UCB. The remaining authors disclose no conflicts.
Publisher Copyright:
© 2021 AGA Institute
PY - 2021/3
Y1 - 2021/3
N2 - The global incidence of inflammatory bowel disease (IBD) has increased considerably during the past few decades.1 IBDs, composed of Crohn's disease (CD) and ulcerative colitis (UC), are characterized by heterogeneous presentation and widely variable clinical course. The therapeutic goals are to induce and maintain remission. Despite the current treatments available, many patients do not achieve this goal.
AB - The global incidence of inflammatory bowel disease (IBD) has increased considerably during the past few decades.1 IBDs, composed of Crohn's disease (CD) and ulcerative colitis (UC), are characterized by heterogeneous presentation and widely variable clinical course. The therapeutic goals are to induce and maintain remission. Despite the current treatments available, many patients do not achieve this goal.
UR - http://www.scopus.com/inward/record.url?scp=85099282436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099282436&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2020.02.017
DO - 10.1016/j.cgh.2020.02.017
M3 - Short survey
C2 - 32068149
AN - SCOPUS:85099282436
SN - 1542-3565
VL - 19
SP - 616
EP - 617
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 3
ER -